Literature DB >> 11104865

Leptin serum levels in cachectic heart failure patients. Relationship with tumor necrosis factor-alpha system.

G S Filippatos1, K Tsilias, K Venetsanou, E Karambinos, D Manolatos, A Kranidis, J Antonellis, F Kardaras, L Anthopoulos, G Baltopoulos.   

Abstract

Cachexia is a strong predictor for mortality in patients with congestive heart failure. To investigate the role of leptin and regulators of apoptosis in cardiac cachexia we compared leptin concentrations and their relation to the TNF system, interleukin 1-beta (IL-1b), and soluble Fas in patients with heart failure with and without cachexia. Patients with cardiac cachexia have increased levels of interleukin-1b compared to non-cachectic heart failure patients [mean(S.E.)=1.11(0.62) vs. 0.02(0.02), P=0.01] and decreased concentrations of leptin [10.79(3.93) vs. 23.24 (8.35), P=0.1]. Leptin levels correlate with TNF-RI in cachectic heart failure patients (r=0.58, P=0.018). The TNF-RI levels were also correlated with Fas, both in all the patients taken together (r=0.5, P=0.006) and in those with cachexia (r=0.52, P=0.036). Our data indicate that more prospective studies are needed to clarify the role of leptin in the pathophysiology of heart failure cachexia.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11104865     DOI: 10.1016/s0167-5273(00)00397-1

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  15 in total

1.  Circulating TNF alpha receptor levels identify older adults who fail to regain weight after acute weight loss.

Authors:  M Yukawa; J Brown-Chang; H S Callahan; C F Spiekerman; D S Weigle
Journal:  J Nutr Health Aging       Date:  2010-10       Impact factor: 4.075

Review 2.  The dynamic interaction between matrix metalloproteinase activity and adverse myocardial remodeling.

Authors:  Joseph S Janicki; Gregory L Brower; Jason D Gardner; Amanda L Chancey; James A Stewart
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

3.  Relationship between RANKL and neuroendocrine activation in elderly males with heart failure.

Authors:  Goran Loncar; Biljana Bozic; Vojkan Cvorovic; Zoran Radojicic; Sinisa Dimkovic; Natasa Markovic; Nenad Prodanovic; Toplica Lepic; Biljana Putnikovic; Vera Popovic-Brkic
Journal:  Endocrine       Date:  2009-11-20       Impact factor: 3.633

4.  Beneficial effects of leptin treatment in a setting of cardiac dysfunction induced by transverse aortic constriction in mouse.

Authors:  Nieves Gómez-Hurtado; Alejandro Domínguez-Rodríguez; Philippe Mateo; María Fernández-Velasco; Almudena Val-Blasco; Rafael Aizpún; Jessica Sabourin; Ana María Gómez; Jean-Pierre Benitah; Carmen Delgado
Journal:  J Physiol       Date:  2017-05-23       Impact factor: 5.182

Review 5.  Pathophysiology and treatment options for cardiac anorexia.

Authors:  Marat Fudim; Gabriel Wagman; Rebecca Altschul; Evin Yucel; Michelle Bloom; Timothy J Vittorio
Journal:  Curr Heart Fail Rep       Date:  2011-06

6.  Leptin levels recover normally in healthy older adults after acute diet-induced weight loss.

Authors:  M Yukawa; E A Phelan; H S Callahan; C F Spiekerman; I B Abrass; D S Weigle
Journal:  J Nutr Health Aging       Date:  2008-11       Impact factor: 4.075

Review 7.  Cachexia in chronic heart failure: endocrine determinants and treatment perspectives.

Authors:  Norman Mangner; Yae Matsuo; Gerhard Schuler; Volker Adams
Journal:  Endocrine       Date:  2012-08-19       Impact factor: 3.633

Review 8.  [Obesity and cardiac cachexia in chronic heart failure].

Authors:  M Clauser; J Altenberger
Journal:  Herz       Date:  2013-09       Impact factor: 1.443

9.  The link of unintentional weight loss to cardiac event-free survival in patients with heart failure.

Authors:  Eun Kyeung Song; Yongjik Lee; Debra K Moser; Rebecca L Dekker; Seok-Min Kang; Terry A Lennie
Journal:  J Cardiovasc Nurs       Date:  2014 Sep-Oct       Impact factor: 2.083

10.  Leptin in anorexia and cachexia syndrome.

Authors:  Diana R Engineer; Jose M Garcia
Journal:  Int J Pept       Date:  2012-02-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.